CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5559-5563

  Strock, Christopher J ^a   Park, Jong In ^a   Rosen, Mark ^a   Dionne, Craig ^c   Ruggeri, Bruce ^c   Jones Bolin, Susan ^c   Denmeade, Samuel R ^a   Ball, Douglas W ^a,b   Nelkin, Barry D ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAZOLE DERIVATIVE; CEP 2563; CEP 701; CEP 751; INDOLOCARBAZOLE DERIVATIVE; PRODRUG; PROTEIN RET; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH; XENOGRAFT;

ANIMALS; CARBAZOLES; CARCINOMA, MEDULLARY; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GROWTH INHIBITORS; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; MUTATION; ONCOGENE PROTEINS; PHOSPHORYLATION; PRODRUGS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0141592764     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hazard, J. B., Hawk, W. A., and Crile, G., Jr., Medullary (solid) carcinoma of thethyroid: a cliniopathologic entity. J. Clin. Endocrinol. Metab., 19: 152, 1959.
2. Hundahl, S. A., Fleming, I. D., Fremgen, A. M., and Menck, H. R. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985-1995. Cancer (Phila.), 83: 2638-2648, 1998.
3. Steiner, A. L., Goodman, A. D., and Powers, S. R. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore), 47: 371-409, 1968.
4. Farndon, J. R., Leight, G. S., Dilley, W. G., Baylin, S. B., Smallridge, R. C., Harrison, T. S., and Wells, S. A., Jr. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br. J. Surg., 73: 278-281, 1986.
5. Mulligan, L. M., Kwok, J. B., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moorc, J. K., Papi, L., and et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (Lond.), 363: 458-460, 1993.
6. Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., and Wells, S. A., Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet., 2: 851-856, 1993.
7. Hofstra, R. M., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W., van Amstel, H. K., Romeo, G., and et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (Lond.), 367: 375-376, 1994.
8. Wohllk, N., Cote, G. J., Bugalho, M. M., Ordonez, N., Evans, D. B., Goepfert, H., Khorana, S., Schultz, P., Richards, C. S., and Gagel, R. F. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab., 81: 3740-3745, 1996.
9. Evans, D. B., Fleming, J. B., Lee, J. E., Cote, G., and Gagel, R. F. The surgical treatment of medullary thyroid carcinoma. Semin. Surg. Oncol., 16: 50-63, 1999.
10. Fleming, J. B., Lee, J. E., Bouvet, M., Schultz, P. N., Sherman, S. I., Sellin, R. V., Friend, K. E., Burgess, M. A., Cote, G. J., Gagel, R. F., and Evans, D. B. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann. Surg., 230: 697-707, 1999.
11. Dralle, H., Scheumann, G. F., Proye, C., Bacourt, F., Frilling, A., Limbert, F., Gheri, G., Henry, J. F., Berner, M., Niederle, B., and et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J. Intern. Med., 238: 357-361, 1995.
12. Skinner, M. A., and Wells, S. A., Jr. Medullary carcinoma of the thyroid gland and the MEN 2 syndromes. Semin. Pediatr. Surg., 6: 134-140, 1997.
13. Lips, C. J., Landsvater, R. M., Hoppener, J. W., Geerdink, R. A., Blijham, G., van Veen, J. M., van Gils, A. P., de Wit, M. J., Zewald, R. A., Berends, M. J., and et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N. Engl. J. Med., 331: 828-835, 1994.
14. Learoyd, D. L., Marsh, D. J., Richardson, A. L., Twigg, S. M., Delbridge, L., and Robinson, B. G. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch. Surg., 132: 1022-1025, 1997.
15. Saad, M. F., Ordonez, N. G., Rashid, R. K., Guido, J. J., Hill, C. S., Jr., Hickey, R. C., and Samaan, N. A. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore), 63: 319-342, 1984.
16. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., and et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science (Wash. DC), 267: 381-383, 1995.
17. Asai, N., Iwashita, T., Matsuyama, M., and Takahashi, M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol., 15: 1613-1619, 1995.
18. Michiels, F. M., Chappuis, S., Caillou, B., Pasini, A., Talbot, M., Monier, R., Lenoir, G. M., Feunteun, J., and Billaud, M. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc. Natl. Acad. Sci. USA, 94: 3330-3335, 1997.
19. Acton, D. S., Velthuyzen, D., Lips, C. J., and Hoppener, J. W. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene, 19: 3121-3125, 2000.
20. Kawai, K., Iwashita, T., Murakami, H., Hiraiwa, N., Yoshiki, A., Kusakabe, M., Ono, K., Iida, K., Nakayama, A., and Takahashi, M. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res., 60: 5254-5260, 2000.
21. Drosten, M., Frilling, A., Stiewe, T., and Putzer, B. M. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery (St. Louis), 132: 991-997; discussion 997, 2002.
22. Carson-Walter, E. B., Smith, D. P., Ponder, B. A., Baylin, S. B., and Nelkin, B. D. Post-transcriptional silencing of RET occurs, but is not required, during raf-I mediated differentiation of medullary thyroid carcinoma cells. Oncogene, 17: 367-376, 1998.
23. Sriuranpong, V., Borges, M. W., Ravi, R. K., Arnold, D. R., Nelkin, B. D., Baylin, S. B., and Ball, D. W. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res., 61: 3200-3205, 2001.
24. Vindelov, L. L., Christensen, I. J., and Nissen, N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry, 3: 323-327, 1983.
25. Carlomagno, F., Salvatore, D., Santoro, M., de Franciscis, V., Quadro, L., Panariello, L., Colantuoni, V., and Fusco, A. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem. Biophys. Res. Commun., 207: 1022-1028, 1995.
26. Fuse, E., Tanii, H., Takai, K., Asanome, K., Kurata, N., Kobayashi, H., Kuwabara, T., Kobayashi, S., and Sugiyama, Y. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans. Cancer Res., 59: 1054-1060, 1999.
27. Hudkins, R. L., Iqbal, M., Park, C. H., Goldstein, J., Herman, J. L., Shek, E., Murakata, C., and Mallamo, J. P. Prodrug esters of the indolocarbazole CEP-751 (KT-6587). Bioorg. Med. Chem. Lett., 8: 1873-1876, 1998.
28. Camoratto, A. M., Jani, J. P., Angeles, T. S., Maroney, A. C., Sanders, C. Y., Murakata, C., Neff, N. T., Vaught, J. L., Isaacs, J. T., and Dionne, C. A. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int. J. Cancer, 72: 673-679, 1997.
29. Dionne, C. A., Camoratto, A. M., Jani, J. P., Emerson, E., Neff, N., Vaught, J. L., Murakata, C., Djakiew, D., Lamb, J., Bova, S., George, D., and Isaacs, J. T. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin. Cancer Res., 4: 1887-1898, 1998.
30. George, D. J., Dionne, C. A., Jani, J., Angeles, T., Murakata, C., Lamb, J., and Isaacs, J. T. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res., 59: 2395-2401, 1999.
31. Levis, M., Allebach, J., Tse, K. F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99: 3885-3891, 2002.
32. Akinaga, S., Sugiyama, K., and Akiyama, T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anticancer Drug Des., 15: 43-52, 2000.
33. Tsuzuki, T., Takahashi, M., Asai, N., Iwashita, T., Matsuyama, M., and Asai, J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene, 10: 191-198, 1995.
34. Takaya, K., Yoshimasa, T., Arai, H., Tamura, N., Miyamoto, Y., Itoh, H., and Nakao, K. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J. Mol. Med., 74: 617-621, 1996.
35. Golden, J. P., DeMaro, J. A., Osborne, P. A., Milbrandt, J., and Johnson, E. M., Jr. Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp. Neurol., 158: 504-528, 1999.
36. Weeraratna, A. T., Dalrymple, S. L., Lamb, J. C., Denmeade, S. R., Miknyoczki, S., Dionne, C. A., and Isaacs, J. T. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin. Cancer Res., 7: 2237-2245, 2001.
37. Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., and Santoro, M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res., 62: 7284-7290, 2002.
38. Lanzi, C., Cassinelli, G., Pensa, T., Cassinis, M., Gambetta, R. A., Borrello, M. G., Menta, E., Pierotti, M. A., and Zunino, F. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int. J. Cancer, 85: 384-390, 2000.
39. Cohen, M. S., Hussain, H. B., and Moley, J. F. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery (St. Louis), 132: 960-967, 2002.
40. Cassinelli, G., Lanzi, C., Pensa, T., Gambetta, R. A., Nasini, G., Cuccuru, G., Cassinis, M., Pratesi, G., Polizzi, D., Tortoreto, M., and Zunino, F. Clavilactones, a novel class of tyrosine kinase inhibitors of fungal origin. Biochem. Pharmacol., 59: 1539-1547, 2000.
41. Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A., Gazit, A., Levitzki, A., and Santoro, M. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res., 62: 1077-1082, 2002.